InVision® platform
Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients
InVisionFirst®Lung
Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients
Radar™
A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform
Our Mission
We are transforming the lives of cancer patients and their families through the power of liquid biopsy
Latest News and Events
Inivata Raises $35 million in Second Close of Series C Financing
Funds will accelerate clinical development of RaDaR minimal residual disease assay and commercialization of InVisionFirst®-Lung Read More
Circulating tumor DNA (ctDNA) clearance as a biomarker in patients with locally advanced NSCLC following chemoradiation
B. Knapp, L. Mezquita, S. Devarakonda, M. Aldea, S. Waqar, K. Pepin, J. Ward, A. Botticella, K. Howarth, C. Knape, C. Morris, R. ... Read More
Clinical Biomarkers & World CDx Europe 2021
Event expiration date display - 24 - 25 MAR 2021
Location: Online Event Read More
Changing Lives
Patients are at the heart of everything we do.
Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives.
This is the story of the first patient Inivata tested.